OR WAIT null SECS
Seattle
Washington
Christopher B. Fox is the lead formulation engineer at the Infections Disease Research Institute
Adjuvant activity can be greatly improved by appropriate formulation of cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG ODNs).